Researchers at UCLA have unveiled startling findings using PSMA-PET imaging that reveal nearly half of patients diagnosed with high-risk prostate cancer might actually have metastases missed by traditional imaging methods.
This revelation could profoundly affect future treatment decisions and patient outcomes, highlighting the necessity of incorporating advanced imaging technologies into standard diagnostic procedures.
Breakthroughs in Prostate Cancer Imaging
Researchers at UCLA Health’s Jonsson Comprehensive Cancer Center have discovered that many cases of high-risk, hormone-sensitive prostate cancer classified as nonmetastatic may actually be more advanced than originally believed.
The study, published today (January 3) in JAMA Network Open, revealed that nearly half of these patients, initially diagnosed as nonmetastatic using traditional imaging, were found to have metastatic disease when assessed with advanced prostate-specific membrane antigen–positron emission tomography (PSMA-PET) imaging. This suggests that conventional imaging often underestimates the extent of cancer spread.
Impact of PSMA-PET on Treatment Decisions
“Our study demonstrates the critical role of PSMA-PET in accurately staging prostate cancer, which can significantly impact treatment decisions and outcomes,” said senior author of the study Dr. Jeremie Calais, director of the Ahmanson Translational Theranostics Division’s clinical research program and associate professor at the department of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA.
This advanced imaging technology plays a critical role in redefining how prostate cancer is staged. PSMA-PET imaging uses tiny amounts of radioactive “tracers,” called radiotracers, that binds to prostate cancer cells, making them visible on PET scans. Unlike conventional imaging, which provides only anatomical details, PSMA-PET offers functional imaging that reveals the cancer’s biological activity, which can significantly improve the accuracy of disease staging.
Changing Clinical Practices with New Imaging Techniques
The clinical adoption of PSMA-PET has changed the landscape of prostate cancer imaging, yet treatment decisions often rely on clinical trials that did not incorporate this advanced imaging technique for patient selection.
To better understand the advantages of PSMA-PET over conventional imaging, researchers conducted a post hoc, retrospective cross-sectional study using data from 182 patients with high-risk recurrent prostate cancers who were thought to have disease limited to the prostate and were eligible for the EMBARK trial.
This clinical trial previously demonstrated that adding enzalutamide, a type of hormone therapy, to androgen deprivation therapy significantly improves metastasis-free survival. However, the trial relied on conventional imaging to classify patients, which researchers believe might have underestimated the disease’s extent in some cases.
In the cohort of patients, the researchers found PSMA-PET detected cancer metastases in 46% of patients, even though traditional imaging had suggested no evidence of cancer spread. Based on PSMA-PET, 24% of the patients even showed 5 or more lesions that had been missed by conventional imaging.
“We anticipated that PSMA-PET would detect more suspicious findings compared to conventional imaging. However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases,” said Dr. Adrien Holzgreve, a visiting assistant professor at the David Geffen School of Medicine and first author of the study.
Implications for Future Research and Clinical Trials
These results challenge the interpretation of previous studies, like the EMBARK trial, and support the inclusion of PSMA-PET for patient selection in clinical and trial interventions in prostate cancer in future major industry-sponsored clinical trials. It also highlights the need to reevaluate treatment strategies and opens the door to potentially curative options for some patients, such as targeted radiotherapy, while raising important questions about integrating new imaging technologies into standard care.
While the current findings underscore PSMA-PET’s potential, researchers are continuing to explore its broader applications through additional studies. More research is needed to understand its impact on long-term patient outcomes and how it can best guide therapy, noted Calais.
“We have good rationales to assume that it is helpful to primarily rely on PSMA-PET findings,” said Holzgreve. “But more high-quality prospective data would be needed to claim superiority of PSMA-PET for treatment-guidance in terms of patient outcome. However, we are confident PSMA-PET will continue to advance prostate cancer staging and guide personalized therapies.”
Ongoing efforts at UCLA include analyzing follow-up data from four UCLA trials to assess how PSMA-PET findings influenced treatment decisions and patient outcomes. Additionally, as part of an international consortium studying over 6,000 patients, the team is investigating the prognostic value of PSMA-PET.
Reference: 3 January 2025, JAMA Network Open.
DOI: 10.1001/jamanetworkopen.2024.52971
News
Water-Resistant Paper Could Revolutionize Packaging and Replace Plastic
A groundbreaking study showcases the creation of sustainable hydrophobic paper, enhanced by cellulose nanofibres and peptides, presenting a biodegradable alternative to petroleum-based materials, with potential uses in packaging and biomedical devices. Researchers aimed to [...]
NIH Scientists Discover Game-Changing Antibodies Against Malaria
Novel antibodies have the potential to pave the way for the next generation of malaria interventions. Researchers at the National Institutes of Health (NIH) have identified a novel class of antibodies that target a previously unexplored region [...]
Surprising Discovery: What If Some Cancer Genes Are Actually Protecting You?
A surprising discovery reveals that a gene previously thought to accelerate esophageal cancer actually helps protect against it initially. This pivotal study could lead to better prediction and prevention strategies tailored to individual genetic [...]
The Cancer Test That Exposes What Conventional Scans Miss
Researchers at UCLA have unveiled startling findings using PSMA-PET imaging that reveal nearly half of patients diagnosed with high-risk prostate cancer might actually have metastases missed by traditional imaging methods. This revelation could profoundly affect future [...]
Pupil size in sleep reveals how memories are processed
Cornell University researchers have found that the pupil is key to understanding how, and when, the brain forms strong, long-lasting memories. By studying mice equipped with brain electrodes and tiny eye-tracking cameras, the researchers [...]
Stanford’s Vaccine Breakthrough Boosts Flu Protection Like Never Before
Stanford Medicine researchers have developed a new method for influenza vaccination that encourages a robust immune response to all four common flu subtypes, potentially increasing the vaccine’s efficacy. In laboratory tests using human tonsil [...]
Water’s Worst Nightmare: The Rise of Superhydrophobic Materials
New materials with near-perfect water repellency offer potential for self-cleaning surfaces in cars and buildings. Scientists from Karlsruhe Institute of Technology (KIT) and the Indian Institute of Technology Guwahati (IITG) have developed a surface [...]
Japanese dentists test drug to help people with missing teeth regrow new ones
Japanese dentists are testing a groundbreaking drug that could enable people with missing teeth to grow new ones, reducing the need for dentures and implants, AFP recently reported. Katsu Takahashi, head of oral surgery at [...]
An AI system has reached human level on a test for ‘general intelligence’
A new artificial intelligence (AI) model has just achieved human-level results on a test designed to measure "general intelligence." On December 20, OpenAI's o3 system scored 85% on the ARC-AGI benchmark, well above the previous AI best [...]
According to Researchers, Your Breathing Patterns Could Hold the Key to Better Memory
Breathing synchronizes brain waves that support memory consolidation. A new study from Northwestern Medicine reports that, much like a conductor harmonizes various instruments in an orchestra to create a symphony, breathing synchronizes hippocampal brain waves to [...]
The Hidden Culprit Behind Alzheimer’s Revealed: Microglia Under the Microscope
Researchers at the CUNY Graduate Center have made a groundbreaking discovery in Alzheimer’s disease research, identifying a critical link between cellular stress in the brain and disease progression. Their study focuses on microglia, the brain’s immune [...]
“Mirror Bacteria” Warning: A New Kind of Life Could Pose a Global Threat
Mirror life, a concept involving synthetic organisms with reversed molecular structures, carries significant risks despite its potential for medical advancements. Experts warn that mirror bacteria could escape natural biological controls, potentially evolving to exploit [...]
Lingering Viral Fragments: The Hidden Cause of Long COVID
Long COVID, affecting 5-10% of COVID-19 patients, might be caused by the enduring presence of the virus in the body. Research suggests that viral fragments, possibly live, linger and lead to symptoms. Addressing this involves antiviral treatments, enhanced [...]
Hidden Scars: How COVID Lockdowns Altered Teen Brains Forever
Research from the University of Washington revealed that COVID-19 lockdowns led to accelerated cortical thinning in adolescents, impacting brain development significantly. This effect was more pronounced in females than males, raising concerns about long-term brain health. The study [...]
Simple Blood Test To Detect Dementia Before Symptoms Appear
UCLA researchers have identified placental growth factor (PlGF) as a potential blood biomarker for early detection of cognitive impairment and dementia. High PlGF levels correlate with increased vascular permeability, suggesting its role in the development [...]
Investing Goldman Sachs asks ‘Is curing patients a sustainable business model?’
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run. “Is curing patients [...]
